A&O Shearman advises Bridgepoint on Axplora’s EUR530 million cross-border senior refinancing

The transaction reinforces the Axplora Group’s financial foundation as it continues to strengthen its market-leading presence and global operations in the pharmaceutical sector.

Axplora, headquartered in Germany, is a leading manufacturer of active pharmaceutical ingredient (API) solutions with ten API sites across Europe, India and the U.S. The refinancing marks a significant milestone for both Axplora and Bridgepoint, supporting the company’s ongoing growth strategy and enabling further investment in innovation and operational excellence.

Robin Harvey, global co-head of private equity at A&O Shearman, commented: “This refinancing demonstrates the strength of our pan-European debt finance practice and our ability to deliver innovative solutions for our clients operating in complex, cross-border environments. We are proud to support Bridgepoint and Axplora as they continue to drive growth and innovation in the pharmaceutical sector.”

A&O Shearman’s cross-border team was led by Robin Harvey and Nihaal Khanna, supported by Jeffrey Ha and Giacomo Geronico Orlandi, together with colleagues from A&O Shearman’s European offices in Germany, Italy, and France.

A&O Shearman has supported Bridgepoint and Axplora’s management team on their financing package since the original acquisition by Bridgepoint in 2020 and its strategic acquisition of Novasep in 2022. The firm’s longstanding relationship with Bridgepoint and Axplora was instrumental in navigating the complexities of this multi-jurisdictional deal.

A&O Shearman’s role in this refinancing underscores the firm’s deep expertise in the pharmaceutical and biotechnology industry and its commitment to supporting clients through every stage of their development.